Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































A Model Act to License Pharmaceutical Representatives
/in Model Legislation and Contracts, Prescription Drug Pricing Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffSection 1. Statement of Legislative Intent; Purpose Whereas pharmaceutical marketing impacts clinical decision-making, outcomes, and resource utilization; Whereas marketing strategies may keep prescription drug prices high by aggressively marketing patented products to limit generic competition; Whereas aggressive marketing of opioids fueled the opioid epidemic; Whereas evidence-based prescribing can reduce health care costs and save lives; […]
Q&A: A Model Act to License Pharmaceutical Representatives
/in Model Legislation and Contracts, Prescription Drug Pricing Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffWhat is a pharmaceutical representative? A pharmaceutical representative markets brand-name prescription drugs directly to health care professionals who decide whether or not to prescribe them. Pharmaceutical representatives include pharmaceutical sales representatives as well as more specialized medical science liaisons. Why should states license pharmaceutical representatives? A sales force focused on influencing health care professionals’ prescribing […]
NASHP’s Proposal for Protecting Consumers from Prescription Drug Price Gouging
/in Model Legislation and Contracts, Prescription Drug Pricing Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Michelle MelloNASHP Launches Next Round of Model Acts to Lower Rx Costs – Preventing Generic Price Gouging
/in Model Legislation and Contracts, Prescription Drug Pricing Blogs, Featured News Home Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Trish Riley, Johanna Butler and Jennifer ReckAs the nation grapples with the pandemic, new research has identified dexamethasone, a low-cost generic drug, as a promising treatment for certain COVID-19 patients. But consumers worry – will its cost remain low? Will new treatments be affordable?
Q&A: A Model Act to Prevent Excessive and Unconscionable Prices for Prescription Drugs
/in Model Legislation and Contracts, Prescription Drug Pricing Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffHow does this model act stop price gouging? Recent price hikes for insulin and other drugs have awakened the public to often unpredictable and extraordinary increases in commonly used drugs. This model act prohibits manufacturers from hiking drug prices outside of certain market conditions that might justify a jump in price. Noncompliant manufacturers face fines […]
An Act to Prevent Excessive and Unconscionable Prices for Prescription Drugs
/in Model Legislation and Contracts, Prescription Drug Pricing Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffSection 1. Statement of Legislative Intent; Purpose The purpose of this Chapter is to protect the safety, health and economic well-being of [name of state] people by guarding them from the negative and harmful impact of excessive and unconscionable prices for prescription drugs. In enacting this Act, the legislature finds that: Access to prescription drugs […]
CMS Proposes Rule to Support Value-Based Purchasing for Drugs
/in Policy Blogs, Featured News Home Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Prescription Drug Pricing, State Employee Health Plans, Value-Based Purchasing /by Jennifer ReckThe Centers for Medicare & Medicaid Services (CMS) has proposed a new rule with provisions designed to advance value-based purchasing (VBP) arrangements with drug manufacturers. Comments about the proposal are due July 20, 2020.
How Waste-Free Formularies Create Savings on Prescription Drugs
/in Policy Blogs, Featured News Home Administrative Actions, Consumer Affordability, Health System Costs, Prescription Drug Pricing /by Jennifer ReckRemoving wasteful drugs from formularies and replacing them with drugs that offer the same benefits at a lower cost, helps state employee health plans and other public purchasers reduce spending without sacrificing value – a critical strategy for savings as states face tremendous budget pressures.
State Rx Purchasing Pool Buy-In Model Gives the Unemployed Access to Discounted Drugs
/in COVID-19 State Action Center Blogs, Featured News Home Administrative Actions, Consumer Affordability, COVID-19, Health System Costs, Model Legislation, Prescription Drug Pricing, State Employee Health Plans, State Rx Legislative Action /by Jennifer ReckStates are experiencing a huge rise in the number of people without health insurance in the wake of mass layoffs resulting from the COVID-19 pandemic and are seeking strategies to protect them from high prescription drug prices. The uninsured are sometimes the only consumers left paying the full list price for a drug, while the […]
Court Rules California Can Share Advance Notice of Rx Price Hikes
/in Policy Blogs, Featured News Home Administrative Actions, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckLast week, a California Court of Appeal lifted an injunction that prevented the state from sharing drug manufacturers’ advance notice of drug price increases. The ruling was a win for states working to advance drug price transparency in the face of manufacturers’ sometimes overly-broad claims of trade secret protection for their prices.